Age-related Macular Degeneration (AMD) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Age-related Macular Degeneration (AMD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Age-related Macular Degeneration (AMD) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Age-related Macular Degeneration (AMD) Understanding and Treatment Algorithm

The market report provides the overview of the Age-related Macular Degeneration (AMD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Age-related Macular Degeneration (AMD) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Age-related Macular Degeneration (AMD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Age-related Macular Degeneration (AMD) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Age-related Macular Degeneration (AMD) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Age-related Macular Degeneration (AMD) market.

Age-related Macular Degeneration (AMD) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Age-related Macular Degeneration (AMD) Report Insights

- Patient Population in Age-related Macular Degeneration (AMD)

- Therapeutic Approaches in Age-related Macular Degeneration (AMD)

- Age-related Macular Degeneration (AMD) Pipeline Analysis

- Age-related Macular Degeneration (AMD) Market Size and Trends

- Age-related Macular Degeneration (AMD) Market Opportunities

- Impact of upcoming Therapies in Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration (AMD) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Age-related Macular Degeneration (AMD) Report Assessment

- Current Treatment Practices in Age-related Macular Degeneration (AMD)

- Unmet Needs in Age-related Macular Degeneration (AMD)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Age-related Macular Degeneration (AMD) market

- Organize sales and marketing efforts by identifying the best opportunities for Age-related Macular Degeneration (AMD) market

- To understand the future market competition in the Age-related Macular Degeneration (AMD) market.

Age-related Macular Degeneration (AMD) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Age-related Macular Degeneration (AMD) Market Overview at a Glance
2.1. Market Share Distribution of Age-related Macular Degeneration (AMD) in 2016
2.2. Market Share Distribution of Age-related Macular Degeneration (AMD) in 2028
3. Disease Background and Overview: Age-related Macular Degeneration (AMD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Age-related Macular Degeneration (AMD) in 7MM
4.3. Total Prevalent Patient Population of Age-related Macular Degeneration (AMD) in 7MM - By Countries
5. Epidemiology of Age-related Macular Degeneration (AMD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.1.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.1.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.1.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.1.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.4.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.4.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.4.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.4.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.5.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.5.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.5.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.5.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.6.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.6.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.6.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.6.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.7.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.7.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.7.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.7.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.8.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.8.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.8.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.8.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD)
5.9.3. Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) *
5.9.4. Sex- Specific Cases of the Age-related Macular Degeneration (AMD) *
5.9.5. Diagnosed Cases of the Age-related Macular Degeneration (AMD)
5.9.6. Treatable Cases of the Age-related Macular Degeneration (AMD)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Age-related Macular Degeneration (AMD)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Age-related Macular Degeneration (AMD)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Age-related Macular Degeneration (AMD) : 7MM Market Analysis
12.1. 7MM Market Size of Age-related Macular Degeneration (AMD)
12.2. 7MM Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD)
12.3. 7MM Market Sales of Age-related Macular Degeneration (AMD) by Products
13. Age-related Macular Degeneration (AMD) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Age-related Macular Degeneration (AMD) in United States
13.1.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in United States
13.1.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Age-related Macular Degeneration (AMD) in Germany
13.2.1.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Germany
13.2.1.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Age-related Macular Degeneration (AMD) in France
13.2.2.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in France
13.2.2.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Age-related Macular Degeneration (AMD) in Italy
13.2.3.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Italy
13.2.3.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Age-related Macular Degeneration (AMD) in Spain
13.2.4.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Spain
13.2.4.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Age-related Macular Degeneration (AMD) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in United Kingdom
13.2.5.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Age-related Macular Degeneration (AMD) in Japan
13.3.2. Percentage Share of drugs marketed for Age-related Macular Degeneration (AMD) in Japan
13.3.3. Market Sales of Age-related Macular Degeneration (AMD) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Table 6: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Table 7: Treatable Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Table 12: Treatable Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Table 15: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Table 16: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Table 17: Treatable Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Table 22: Treatable Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Table 27: Treatable Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Table 31: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Table 32: Treatable Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Table 37: Treatable Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 42:7MM- Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 45: United States-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 48: Germany-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 51: France-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 54: Italy-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 57: Spain-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 60:UK-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Table 63: Japan-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Figure 7: Treatable Cases of the Age-related Macular Degeneration (AMD) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Figure 12: Treatable Cases of the Age-related Macular Degeneration (AMD) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Figure 16: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Figure 17: Treatable Cases of the Age-related Macular Degeneration (AMD) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Figure 22: Treatable Cases of the Age-related Macular Degeneration (AMD) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Figure 27: Treatable Cases of the Age-related Macular Degeneration (AMD) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Figure 32: Treatable Cases of the Age-related Macular Degeneration (AMD) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Figure 37: Treatable Cases of the Age-related Macular Degeneration (AMD) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 42:7MM- Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 45: United States-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 48: Germany-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 51: France-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 54: Italy-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 57: Spain-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 60:UK-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Age-related Macular Degeneration (AMD) in USD MM (2016-2028)
Figure 63: Japan-Market Share Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Age-related Macular Degeneration (AMD) by Therapies in USD MM (2016-2028)

  • Global Artificial Tears Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 91
    Artificial tears are lubricant eye drops used to treat The dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations. The global Artificial Tears market was valued at US$ 2921.6 million in 2023 and is anticipated to reach US$ 5240.1 million by 2030, witnessing a CAGR of 8.6% during The forecast period 2024-2030. The industry's leading producers are Aller......
  • Global Contact Lens Solution Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 96
    Contact lens solution is a kind of solution that is used to contact lens with The function of cleaning, disinfection, rinsing or preservation, it can also alleviate The eyeball discomfort which caused by wear The contact lens. Contact lens solution can direct contact eyeball, so it must be accord with industrial standard. The global Contact Lens Solution market was valued at US$ 4087.6 million in 2023 and is anticipated to reach US$ 5323.5 million by 2030, witnessing a CAGR of 3.8% ......
  • Global Latanoprost Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 82
    Latanoprost drops is a clear colorless liquid and a medication used to treat increased pressure inside The eye. Onset of effects is usually within four hours, and they last for up to a day. Latanoprost is used to treat high pressure inside The eye due to glaucoma (open angle type) or other eye diseases (e.g., ocular hypertension). It is similar to a natural chemical in The body (prostaglandin) and works by regulating The flow of fluid within The eye which results in lower pressure. Lowerin......
  • Global Contact Lens Solution Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Contact Lens Solution market: According to our latest research, the global Contact Lens Solution market looks promising in the next 5 years. As of 2022, the global Contact Lens Solution market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Contact ......
  • Global Dry Eye Syndrome Drugs Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 82
    The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive......
  • Global Eye Drops & Lubricants Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Eye Drops & Lubricants market size was valued at US$ 8841.8 million in 2023. With growing demand in downstream market, the Eye Drops & Lubricants is forecast to a readjusted size of US$ 9780.8 million by 2030 with a CAGR of 1.5% during review period. The research report highlights the growth potential of the global Eye Drops & Lubricants market. Eye Drops & Lubricants are expected to show stable growth in the future market. H......
  • Global Conjunctivitis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 98
    According to our LPI (LP Information) latest study, the global Conjunctivitis market size was valued at US$ 3482.7 million in 2023. With growing demand in downstream market, the Conjunctivitis is forecast to a readjusted size of US$ 3908 million by 2030 with a CAGR of 1.7% during review period. The research report highlights the growth potential of the global Conjunctivitis market. Conjunctivitis are expected to show stable growth in the future market. However, product differentiation, r......
  • Global Contact Lens Solution Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 118
    According to our LPI (LP Information) latest study, the global Contact Lens Solution market size was valued at US$ 3998.7 million in 2023. With growing demand in downstream market, the Contact Lens Solution is forecast to a readjusted size of US$ 5241.5 million by 2030 with a CAGR of 3.9% during review period. The research report highlights the growth potential of the global Contact Lens Solution market. Contact Lens Solution are expected to show stable growth in the future market. Howev......
  • Global Latanoprost Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Latanoprost market size was valued at US$ 1344.2 million in 2023. With growing demand in downstream market, the Latanoprost is forecast to a readjusted size of US$ 1574.2 million by 2030 with a CAGR of 2.3% during review period. The research report highlights the growth potential of the global Latanoprost market. Latanoprost are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs